ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

Mucommune, a Morrisville-based biotechnology company with roots at the University of North Carolina at Chapel Hill, has been ...

Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...

Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

For centuries, newer technologies have been met with initial hesitancy — the railroad, the telephone, and, more recently, the electric car. These transformative innovations were first introduced and ...

Chimeric antigen receptor (CAR) T-cell therapy has been an exciting area of development for autoimmune disease treatment. Previous reports had not mentioned any particular constellation of adverse ...